Gepotidacin, a new first-in-class antibiotic for treating uncomplicated urinary tract infection
- PMID: 38342129
- DOI: 10.1016/S0140-6736(23)02697-1
Gepotidacin, a new first-in-class antibiotic for treating uncomplicated urinary tract infection
Conflict of interest statement
ASMA has acted as a consultant for the UK National Institute for Health and Care Excellence with regard to urinary tract infection study design, outside of the area of work commented on here. He is the Medical Director of Convatec, a medical device company that produces devices for incontinence, outside of the submitted work. CSA has received speaker fees from Viatris to give a talk on chronic urinary tract infections.
Comment on
-
Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials.Lancet. 2024 Feb 24;403(10428):741-755. doi: 10.1016/S0140-6736(23)02196-7. Epub 2024 Feb 8. Lancet. 2024. PMID: 38342126 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
